gmp
gmp

Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              ABL Bio

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              KOREA, REPUBLIC OF Korea, Republic Of

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Food & Nutrition Conference 2020

              Participation Not Confirmed

              Update your events

              HiFiBiO Therapeutics Announces a Global Strategic Partnership with ABL Bio for the Co-Development of a SARS-CoV-2 Neutralizing Antibody

              Contact the Supplier

              Lead Product(s): HFB30132A

              Therapeutic Area: Infections and Infectious Diseases Product Name: HFB30132A

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: HiFiBiO Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership September 14, 2020

              Details:

              Partnership with ABL Bio supports HiFiBiO Therapeutics' rapid clinical advancement of its SARS-CoV-2 neutralizing antibody, HFB30132A, for the treatment of COVID-19 patients.

              PharmaCompass__DigitalAd